C. Burcin Taner
Mayo Clinic
116 Papers
543 Citations
C. Burcin Taner is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Liver transplantation & Medicine. The author has an hindex of 24, co-authored 101 publications.
Chat about Author
Papers
Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors
C. Burcin Taner,Ilynn G. Bulatao,Darrin L. Willingham,Dana K. Perry,Lena Sibulesky,Surakit Pungpapong,Jaime Aranda-Michel,Andrew P. Keaveny,David J. Kramer,Justin H. Nguyen +9 more
TL;DR: A link between the development of IC and the asystole‐to‐cross clamp duration is established and Procurement techniques that prolong the nonperfusion period increase the risk for the developed IC in DCD liver grafts.
154
Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors.
TL;DR: The national outcomes for DCD LT have improved over the last 12 years, and this change was associated with modifications in both recipient and donor selection.
121
Donor safety and remnant liver volume in living donor liver transplantation.
C. Burcin Taner,Murat Dayangac,Baris Akin,Deniz Balci,Suleyman Uraz,Cihan Duran,Refik Killi,Omer Ayanoglu,Yildiray Yuzer,Yaman Tokat +9 more
TL;DR: The use of donors with less than 30% remnant liver volume is highly debatable as donor safety should be of utmost importance in living donor liver transplantation.
99
Surgical treatment of gallbladder cancer.
TL;DR: The results support radical surgical resection for the treatment of gallbladder cancer to improve patient survival and all variables except sex, tumor grade, and adjuvant therapy were statistically significant predictors for the survival of patients with gallbladders cancer.
86
A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.
Andrea Schlegel,Andrea Schlegel,BONG YOO,Andrea Schlegel,Marjolein van Reeven,Kristopher P. Croome,Alessandro Parente,Annalisa Dolcet,Jeannette Widmer,Jeannette Widmer,Nicolas Meurisse,Riccardo De Carlis,Amelia J. Hessheimer,Ina Jochmans,Matteo Mueller,Otto B. van Leeuwen,Amit Nair,Amit Nair,Koji Tomiyama,Ahmed Sherif,Mohamed Elsharif,Philipp Kron,Philipp Kron,Danny van der Helm,Daniel Borja-Cacho,Humberto Bohorquez,Desislava Germanova,Daniele Dondossola,Tiziana Olivieri,Stefania Camagni,Andre Gorgen,Damiano Patrono,Matteo Cescon,Sarah Croome,Rebecca Panconesi,Rebecca Panconesi,Mauricio Flores Carvalho,Matteo Ravaioli,Juan Carlos Caicedo,George E. Loss,V. Lucidi,Gonzalo Sapisochin,Renato Romagnoli,Wayel Jassem,Michele Colledan,Luciano De Carlis,Giorgio Rossi,Fabrizio Di Benedetto,Charles Miller,Bart van Hoek,Magdy Attia,Peter Lodge,Roberto Hernandez-Alejandro,Olivier Detry,Cristiano Quintini,Gabriel C. Oniscu,Constantino Fondevila,Massimo Malagó,Jacques Pirenne,Jan Nm Ijzermans,Robert J. Porte,Philipp Dutkowski,C. Burcin Taner,Nigel Heaton,Pierre-Alain Clavien,Wojciech G. Polak,Paolo Muiesan,Paolo Muiesan,Paolo Muiesan,Ian P.J. Alwayn,Aad P. van der Berg,Margherita Carbonaro,Marco P. A. W. Claasen,Marco P. A. W. Claasen,Amna Daud,Vincent E de Meijer,Herold J. Metselaar,Diethard Monbaliu,Maite Paolucci,Sofie Vets,Erin Winter +80 more
TL;DR: In this paper, the best possible outcomes after liver transplantation of grafts donated after circulatory death (DCD) were defined using the concept of benchmarking, and the following benchmark cut-offs for the most relevant outcome parameters were developed: ICU and hospital stay: ≤3 and ≤16 days; primary non function: ≤2.5%; renal replacement therapy: ≤9.6%; ischemic cholangiopathy: ≤16.4%.
77